Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | CDC25A | P30304 | 1/20 | 0.34 |
| ▸ | CDC25B | P30305 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6505119 | 0.70 | GAA (0.47) | L3MBTL1ALDH1A1GAAKMT2A | |
| SCHEMBL9755397 | 0.68 | CDC25A (0.38) | PTPN1IDO1CDC25ACDC25BHCRTR1 | |
| SCHEMBL29711937 | 0.66 | GPR3 (0.41) | CDC25BALDH1A1CYP1A2CYP2D6KMT2A | |
| SCHEMBL224931 | 0.66 | GPR3 (0.41) | CDC25BALDH1A1CYP1A2CYP2D6KMT2A | |
| Methylamine SCHEMBL27789000 | 0.65 | GPR3 (0.41) | CYP1A2KMT2A | |
| SCHEMBL27818816 | 0.64 | GPR3 (0.39) | CDC25BALDH1A1CYP1A2CYP2D6KMT2A | |
| Hydrochloric Acid SCHEMBL27768859 | 0.64 | GPR3 (0.39) | CDC25BALDH1A1CYP1A2CYP2D6KMT2A | |
| SCHEMBL6219365 | 0.64 | KMT2A (0.34) | CDC25ACDC25BALDH1A1CYP1A2CYP2C9 | |
| Trimethylammonium SCHEMBL27767358 | 0.63 | GPR3 (0.50) | ALDH1A1KMT2A | |
| SCHEMBL3907869 | 0.63 | KMT2A (0.59) | L3MBTL1ALDH1A1CYP1A2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2124919-A2 | METHODS FOR MODULATING BONE FORMATION AND MINERALIZATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-12-02 | — | — | EP | claimed |
| US-20080318987-A1 | METHODS FOR MODULATING BONE FORMATION AND MINERALIZATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-25 | — | — | US | claimed |
| WO-2008103314-A2 | METHODS FOR MODULATING BONE FORMATION AND MINERALIZATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2008-08-28 | — | — | WO | claimed |
| EP-2124919-A2 | METHODS FOR MODULATING BONE FORMATION AND MINERALIZATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080318987-A1 | METHODS FOR MODULATING BONE FORMATION AND MINERALIZATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-25 | — | — | US | disclosed |
| WO-2008103314-A2 | METHODS FOR MODULATING BONE FORMATION AND MINERALIZATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318987-A1 | METHODS FOR MODULATING BONE FORMATION AND MINERALIZATION | BMP4, BMP2, SOST | PTPN1 3441/4885IDO1 4527/4885CDC25A 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.